Tags : Gene Therapies

Biotech

BioMarin Collaborates with Allen Institute to Develop Gene Therapies for

Shots: BioMarin will receive an exclusive license to each program for research, development, and commercialization of the gene therapies The collaboration will utilize Allen institute technologies to develop new gene therapies for rare genetic diseases of CNS by targeting gene expression to specific cells Allen Institute has developed modified engineering AAVs to carry genes on […]Read More

Biotech

Vertex Signs a License Agreement with Obsidian Therapeutics to Discover

Shots: Obsidian to receive $75M in equity, up front, research milestones and is eligible to receive ~$1.3B as research, development, regulatory, and commercial milestones across up to five potential programs. Additionally, Obsidian will receive royalties on sales of products that emerge from the collaboration Obsidian will deploy its cytoDRiVE platform to discover controllable genetic therapies […]Read More

Biotech

Almirall and Tyris Collaborate to Develop Next Generation Gene Therapies

Shots: Tyris to receive up front, research milestone along with research funding and will be responsible for generating clinical lead candidates and will further progress them to clinical development Almirall to get an exclusive option to acquire gene therapies and progress them through clinical development to commercialization The collaboration will integrate Tyris’s non-viral based gene […]Read More

Biotech

Takeda Collaborates with Carmine for Non-Viral Gene Therapies Worth Up

Shots: The two companies signed a research agreement to discover, develop and commercialize transformative non-viral gene therapies for two rare disease targets using Carmine’s REGENT technology, based on red blood cell extracellular vesicles (RBCEV) Carmine to receive upfront, research funding, up to $900M milestones along with royalties on sales of therapies. Following the completion of […]Read More

Biotech

Takeda Collaborates with Codexis to Advance Novel Gene Therapies for

Shots: Codexis to receive an upfront payment, reimbursement for research and development fees, development and commercial milestones along with royalties on sales of any commercial product developed under the collaboration The alliance will initially work on three programs to develop novel gene therapies for lysosomal storage disorders and blood factor deficiencies. Codexis will create the […]Read More

Biotech

Fresenius Kabi Forms a Joint Venture in Collaboration with Bio-Techne

Shots: The JV leverages the expertise of three companies that includes Wilson Wolf’s G-Rex technology, BioTechne’s proteins, reagents, media, and gene-editing technologies and Fresenius Kabi’s Lovo cell processing system washes, concentrates and harvests cells The JV focus on providing scalable manufacturing technologies and processes required to develop and commercialize new cell and gene therapies. All […]Read More

Biotech

Sarepta Signs a License Agreement with Stride Bio to Develop

Shots: The companies collaborated to develop in vivo AAV-based therapies for up to eight central nervous system and neuromuscular targets. StrideBio will be responsible for research, development and manufacturing of the first four CNS targets which include MECP2 (Rett syndrome), SCN1A (Dravet syndrome), UBE3A (Angelman syndrome), and NPC1 (Niemann-Pick) Stride Bio to receive $48M upfront […]Read More

Biotech

REGENXBIO Launches a Manufacturing Facility for Developing Gene Therapies Based

Shots: REGENXBIO plans to construct a cGMP manufacturing facility in Rockville, Maryland to produce gene therapy vectors based on NAV technology at scales up to 2,000L using its platform suspension cell culture process The addition of new cGMP manufacturing facility complements current external manufacturing capabilities, enabling a supply of NAV vectors from both internal and […]Read More

Biotech

Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene

 Shots: StrideBio to receive $30M upfront & near term pre-clinical milestones, $680M as development and commercial milestones & royalties on global sales of products. Takeda to get rights for clinical development and commercialization of selected products developed StrideBio will take care of preclinical development & manufacturing of in vivo AAV based gene-therapies for Takeda’s three […]Read More